D-VENIZ (Desvenlafaxine) is a prescription medicine applied across domains where additional symptomatic support is needed for Major Depressive Disorder (MDD) in adults. This medicine is commonly used to help with depression. Its clinical application is relevant in conditions characterized by significant symptomatic burden associated with moderate-to-severe and recurrent episodes. The primary indications are relevant in contexts marked by increased discomfort or tension, such as the feelings of sadness, emotional emptiness, and hopelessness.

D-VENIZ helps address symptom clusters that may become intense or disruptive, including fatigue, sleep abnormalities, and difficulties with concentration, as well as the loss of interest or pleasure (anhedonia). The medication is often used during phases when symptoms become more noticeable and supportive relief is needed, which may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Support for Functional Stability

The medication is used for managing symptoms that interfere with daily functioning, such as fatigue and concentration deficits. By easing these manifestations, it supports the patient during difficult episodes by easing distress and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use D-VENIZ — official regulatory information

This section describes the officially documented population eligibility rules for D-VENIZ (Desvenlafaxine), based strictly on government regulatory documents.

Eligibility scope	Status
Populations for whom use is allowed	Adults (18 years and older) for the labeled indication.
Populations for whom use is contraindicated	Patients with known hypersensitivity to desvenlafaxine, venlafaxine, or formulation components.
	Patients currently taking a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of stopping one.

Age-related eligibility rules	Condition-specific restrictions
Pediatric (<18): Use not approved; safety and efficacy are not established.	Severe Renal/Hepatic Impairment: Use is restricted and requires special limitations due to reduced clearance.
Older Adults (65+): Use is permitted, but the potential for reduced organ clearance should be considered.	Uncontrolled Hypertension: Blood pressure must be controlled prior to initiating treatment.
	Untreated Narrow-Angle Glaucoma: Eligibility is restricted due to potential risk.

Pregnancy and Lactation Eligibility Status

Use during pregnancy, particularly in the third trimester, is conditional, with regulatory documents noting the risk of neonatal complications. During lactation, use is restricted as the drug is present in human milk, and a risk/benefit assessment must be made.

---

Connection to the overall eligibility profile

Regulatory authorities define the boundaries for D-VENIZ use through absolute contraindications and specific restrictions. These rules classify populations that are wholly excluded (e.g., MAOI users) and populations where use is conditional, based on age, organ function, or pre-existing clinical conditions, ensuring compliance with established safety profiles.

D-VENIZ Interactions with other medicines and products

Official regulatory information addresses interactions across pharmacodynamic and pharmacokinetic classifications, defining specific restrictions for co-administration.

Classification	Interacting Agents and Requirement
Contraindicated Combinations	MAOIs (intended to treat psychiatric disorders), Linezolid, and Intravenous Methylene Blue. These combinations are prohibited due to the risk of Serotonin Syndrome.
Serotonergic Risk	Other serotonergic agents (e.g., Triptans, Tramadol, Lithium, St. John's Wort) require monitoring due to the additive risk of Serotonin Syndrome.
Hemostatic Interference	Drugs that affect coagulation or platelet function, such as NSAIDs, Aspirin, and Warfarin, carry a documented increased risk of bleeding events.
Pharmacokinetic Effect	D-VENIZ acts as a weak inhibitor of the CYP2D6 enzyme. Co-administration formally results in increased exposure (AUC/Cmax) of drugs that are primarily substrates of CYP2D6.

Mandatory Timing and Clearance Restrictions

The regulatory label mandates strict washout periods when initiating or discontinuing an MAOI for psychiatric use: at least 14 days must separate the MAOI from D-VENIZ initiation, and 7 days must separate D-VENIZ discontinuation from MAOI initiation. The official profile also notes that individuals with hepatic or renal impairment may experience a potential for increased plasma concentrations due to slower elimination. Although food does not alter bioavailability, regulatory guidance advises that alcohol consumption should be avoided due to the potential for increased central nervous system effects.

D-VENIZ (desvenlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) that acts within the central nervous system. Its primary biological targets are the serotonin transporter (SERT) and the norepinephrine transporter (NET), both located on the presynaptic neuronal membrane. The interaction type is inhibitory, where the molecule binds to and blocks the function of these reuptake transporters.

This blockade prevents the reabsorption of the neurotransmitters serotonin and norepinephrine from the synaptic cleft back into the presynaptic neuron. The direct intracellular consequence is a reduced rate of monoamine clearance from the synapse. This process leads to a downstream cascade of increased and prolonged concentrations of free serotonin and norepinephrine within the synaptic cleft. The sustained elevation in extracellular monoamines results in enhanced neurotransmission via increased stimulation of postsynaptic serotonin and norepinephrine receptors. The system-level physiological consequence is a generalized modulation of serotonergic and noradrenergic signaling pathways in the brain.

D-VENIZ is administered exclusively through the oral route as an extended-release tablet. The specialized design of the tablet requires it to be swallowed whole with fluid; it must not be divided, crushed, chewed, or dissolved, as this would interfere with the controlled-release mechanism necessary for consistent daily exposure.

The standard labeled regimen for adults is 50 mg taken once daily. This dose serves as the recommended therapeutic level, as doses greater than 50 mg per day have not been shown to provide additional clinical benefit. To maintain stable drug levels, the dose should be taken at approximately the same time each day, and its administration is flexible, being permissible with or without food.

Treatment for the main condition often requires a course of several months or longer of sustained therapy. The protocol for ending treatment mandates a gradual dose reduction to support the transition, which is when the available 25 mg strength may be used. Furthermore, usage guidelines require specific adjustments based on a patient’s physiological status. For example, patients with moderate to severe renal or hepatic impairment must be prescribed reduced maximum daily doses to account for diminished drug clearance, which may involve a 25 mg/day or 50 mg every-other-day schedule for severe renal impairment.

Research evidence / Overview of studies for D-VENIZ

Research evidence for D-VENIZ exists primarily in studies that explore how symptoms change over time in adults diagnosed with Major Depressive Disorder (MDD). The studies contribute to the broader evidence landscape by describing the patterns observed in controlled clinical settings.

---

Evidence for Use in Major Depressive Disorder (MDD) in Adults

The evidence base for D-VENIZ is primarily derived from studies that compared measurements to those of a placebo (an inactive substance) in adult outpatients with MDD. These studies were designed as Randomized Controlled Trials (RCTs), a standard method for gathering evidence.

This design was used in research examining episodic symptom patterns in adult outpatients diagnosed with Major Depressive Disorder. The primary research focused on outcomes related to symptom intensity or variability as measured by structured clinical tools, such as the Hamilton Rating Scale for Depression (HAM-D) and the Montgomery–Åsberg Depression Rating Scale (MADRS). Research also explored outcomes reflecting daily functioning or activity level using scales like the Sheehan Disability Scale (SDS). This combined evidence reported measurements of symptom score changes and ratings on global status scales relative to placebo over the short-term treatment period. Research also highlights changes measured during the study period, which contextualizes how patients reported their experience when D-VENIZ was studied for short-term symptom changes.

---

Evidence for Preventing the Recurrence of Depression

Studies were conducted in research contexts involving stable symptoms, with the aim of evaluating the durability of stability over time. These studies used trials known as randomized withdrawal (maintenance) studies.

In this research design, adult patients with MDD who had achieved a stable response after a period of treatment were observed in a double-blind setting. The trials were structured to monitor the time elapsed until relapse (or the return of significant depressive symptoms) in the observed populations.

Findings describe patterns observed in the studies, reporting a measured time to symptomatic return in patients who continued D-VENIZ that was greater than the time reported for those who switched to placebo. This evidence contributes to understanding the long-term patterns of maintaining the observed response.

---

Long-Term Studies and Durability of Response

Beyond the acute 8-week trials, studies were structured to provide insight into outcomes over longer periods. These long-term studies, including open-label extensions and controlled randomized withdrawal trials, followed patients for periods that could range from six months up to about one year.

These studies focused on monitoring the durability of the initial response reported. Research describes how symptoms evolved in the observed populations over these defined time intervals. While these trials provide context regarding the study's design and follow-up, the evidence for stability in controlled, randomized settings is mostly limited to periods up to six months.

---

Evidence in Specific Populations

Research explored D-VENIZ in specific subgroups to understand how data show patterns related to different demographics.

• Children and Adolescents: Studies explored the medicine's use in children and adolescents with MDD. In these short-term, placebo-controlled trials, the research focusing on episodes where symptoms became more noticeable did not report measurements that differed significantly from those reported with placebo on the primary outcome. Data for certain groups, therefore, remain insufficient.
• Older Adults: Subgroup analyses of older adults (age 65 and over) were evaluated in the core MDD research.

---

Understanding Limitations and Research Gaps

The evidence highlights what is known—and what is still uncertain—about D-VENIZ, according to regulatory and scientific reviews.

• Statistical Power: One limitation is that the evaluation of acute efficacy required a post-hoc pooled analysis of multiple short-term trials to establish robust statistical patterns.
• Limited Comparative Data: Comparative evidence is lacking for comprehensive head-to-head trials against all other classes of antidepressants, meaning research does not fully provide insight into relative measurements of symptom change.
• Long-Term Follow-up: While relapse prevention trials exist, there is limited information for long-term outcomes that exceed the six-month controlled maintenance period.

Common questions about D-VENIZ (FAQ)

---

Q: How long does it typically take to feel the initial effects of D-VENIZ?

Studies and official information indicate that it may take a period of time before an effect is observed. While clinical trials are often structured over a full course of treatment, regulatory guidance notes that in general, it may take several weeks of consistent daily use before a person reports feeling an initial change or effect.

Q: Is it normal to feel a bit nauseous when first starting D-VENIZ?

Nausea is listed in regulatory documents as a very common adverse reaction reported in clinical studies. Official information indicates that common reactions, like nausea, may be experienced at the start of treatment. It is noted that these effects are often transient, meaning they are short-lived and may lessen over time.

Q: Can D-VENIZ cause weight gain?

The official adverse reaction lists consistently report side effects like decreased appetite and decreased weight in patients using the medicine. Weight gain itself is generally not listed as one of the commonly reported side effects in the regulatory documentation.

Q: Is D-VENIZ safe to use in older adults (seniors)?

Regulatory eligibility documents state that use is allowed in adults age 65 and over. Official information advises that this population may have an increased incidence of orthostatic hypotension, which is dizziness or lightheadedness upon standing up. It is also noted that potential for reduced organ clearance may require special consideration when determining the appropriate regimen.

Q: Does D-VENIZ affect sleep?

Official regulatory documents list both insomnia (difficulty falling or staying asleep) and somnolence (unusual drowsiness or sleepiness) as common adverse reactions reported in clinical studies. These are two examples of how the medicine may affect sleep patterns.

Q: Can D-VENIZ be used during pregnancy, according to regulatory information?

Regulatory documents state that use during pregnancy is conditional, requiring a risk/benefit assessment. Official documents note that there is a risk of neonatal complications, such as breathing or feeding difficulties, for infants when the medicine is used during the late stages of pregnancy.

Q: Can D-VENIZ be taken with common pain relievers like ibuprofen?

Regulatory guidance advises caution when D-VENIZ is combined with drugs that affect blood clotting, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. This combination carries a documented increased risk of bleeding events, and it is important to be aware of this potential interaction.

Q: What information is available regarding D-VENIZ and fertility?

Official adverse reaction lists commonly report male sexual function disorders in clinical studies. However, the regulatory information does not contain an explicit statement or warning concerning overall reproductive fertility for either sex.

Q: Is there a generic version of D-VENIZ available?

The active ingredient in D-VENIZ, known as desvenlafaxine, is available in generic extended-release tablet form. This information is noted in government drug listings of approved medicines.

Q: Is D-VENIZ described as a 'controlled substance' in official records?

Official regulatory labeling explicitly states that D-VENIZ (desvenlafaxine) is not listed as a controlled substance under the Controlled Substances Act in the United States.

Q: Are there any specific foods that interact with D-VENIZ?

Official product information states that the drug may be taken with or without food. This is because consuming food generally does not alter the drug's absorption into the body, and no specific food items are restricted by regulatory documents.

Q: If I miss a dose of D-VENIZ, what do regulatory guidelines say?

Regulatory guidelines state that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Regulatory guidelines specify that two doses should not be taken at once to make up for a missed dose.

Q: Does D-VENIZ require special monitoring while taking it?

Official guidelines require regular monitoring of blood pressure, which must be controlled prior to beginning treatment. Additionally, because of the Boxed Warning, patients of all ages must be closely monitored for worsening mood or the emergence of suicidal thoughts or behaviors.

Q: Is D-VENIZ a stimulant?

The drug is officially classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). While this mechanism increases levels of norepinephrine, which may cause effects like insomnia or anxiety, the drug is not classified as a traditional stimulant by regulatory bodies.

Q: Is it true that D-VENIZ is only for severe cases?

The medicine is indicated for the treatment of Major Depressive Disorder (MDD) in adults. Official regulatory information does not restrict its use to only those who have been diagnosed with severe symptoms of the condition.

Q: What are the warnings about combining D-VENIZ with other prescription medications?

Regulatory documents list a high risk of Serotonin Syndrome when combined with certain medications like MAOIs, Linezolid, or Intravenous Methylene Blue, which are therefore contraindicated (forbidden). It also warns of an increased risk of bleeding when used with other drugs that affect coagulation, such as Warfarin.

Q: Are there official registry or tracking programs for D-VENIZ use?

Regulatory agencies require that patients, particularly young adults, be closely monitored for the emergence of suicidal thoughts and behaviors due to the Boxed Warning. This required monitoring serves as a safety tracking element outlined in official documentation.

Q: Does taking D-VENIZ at a certain time of day matter?

Official guidance advises that the medicine should be taken at approximately the same time each day to help maintain stable drug levels in the body. The time of day itself (e.g., morning or evening) is generally flexible.

Q: How quickly is D-VENIZ processed and removed from the body?

Official pharmacokinetic data indicates that the drug has a half-life of approximately 10 to 11 hours in the body. The half-life refers to the time it takes for the concentration of the medicine in the blood to decrease by half.

Q: Are there different strengths or formulations of D-VENIZ available?

The product is supplied as extended-release tablets in multiple strengths. The dosage forms and strengths listed in regulatory documents typically include 25 mg, 50 mg, and 100 mg doses.

Q: Has D-VENIZ been studied in diverse patient populations?

Clinical trials for D-VENIZ typically enrolled men and women across a broad age range, and included subgroup analyses for specific populations, such as older adults. These studies are often multi-site and designed to meet the regulatory requirements for approval.

Q: Is D-VENIZ available in liquid form?

The official dosage form is an extended-release tablet intended for oral administration. Regulatory guidance specifies that the tablet must be swallowed whole and cannot be crushed, chewed, or dissolved.

Q: What are the major themes of research evidence for D-VENIZ?

According to regulatory-reviewed evidence, the major research themes are: establishing short-term changes in symptoms for adults with Major Depressive Disorder (MDD), and studies focused on the prevention of symptom recurrence over time (maintenance studies).

Storage and Disposal of D-VENIZ

Storage and disposal of D-VENIZ (desvenlafaxine extended-release tablets) must follow official regulatory requirements to maintain product stability and ensure safety.

Category	Regulatory Requirement
Temperature Range	Store at controlled room temperature between 68°F and 77°F (20°C to 25°C).
Handling	Tablets must be swallowed whole and must not be crushed, chewed, divided, or dissolved to preserve the extended-release mechanism.
Child Safety	The medication must be kept out of the sight and reach of children and pets.
Disposal	Disposal should use an official drug take-back program or involve mixing the medication with an unappealing substance before discarding in the household trash.

Before discarding the container, all personal identifying information should be scratched off the label. The product is supplied in bottles with a child-resistant closure.